NMN & NR: the biomarker moves, the outcome is missing

NMN and NR are the two most popular NAD+ precursors, and they sit at an unusually honest place on the map: the biology is genuinely interesting, the biomarker genuinely moves, and the thing you actually care about — living longer or feeling better — is genuinely unproven. Holding all three of those at once is the whole point of this entry.

Start with the part that’s real. NAD+ is a coenzyme every cell uses for energy metabolism and DNA repair, and its levels decline with age. In animals, boosting NAD+ with precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) can improve metabolic function and, in some models, extend lifespan. That is a legitimate, well-reviewed hypothesis, not marketing invention. The question is whether any of it carries over to humans — and that is where the story thins out fast.

What the evidence actually shows

The human data are consistent on exactly one thing: these compounds raise blood NAD+. In a randomized crossover trial of 24 healthy middle-aged and older adults, six weeks of NR was well tolerated and reliably elevated NAD+ in blood, with a hint (underpowered, exploratory) of lower blood pressure. In a larger NMN trial — 80 healthy adults, doses up to 900 mg/day for 60 days — NMN raised blood NAD+ in a dose-dependent way and was again well tolerated over the short term.

So the precursor-to-biomarker link is grade B: real, replicated, unsurprising. But read what those trials measured. They measured a number in your blood. They did not show you live longer, get sick less, or age more slowly. Nobody has run the trial that matters — a long, hard-endpoint study of whether raising NAD+ changes disease or death in people — and until someone does, “raises NAD+” and “improves your health” are two different claims, and only the first one is supported. That gap is the honest headline, and it’s why the overall grade here is C, not B.

Why the biomarker isn’t the point

It’s worth being explicit about why this matters, because “it moves my NAD+” sounds like an outcome and isn’t one. The history of medicine is full of interventions that improved a biomarker and did nothing — or worse — for the person. A drug can raise HDL and not prevent a single heart attack. Surrogate endpoints are hypotheses, not results. NAD+ is a plausible surrogate with a nice mechanistic story, which is a reason to keep studying it, not a reason to assume the benefit is already banked.

The regulatory mess (NMN specifically)

NMN’s legal status has genuinely whipsawed, and it’s worth knowing. In late 2022 the FDA took the position that NMN was excluded from the dietary-supplement definition because it had been authorized for investigation as a drug before being marketed as a supplement — a technical but real preclusion. That ruling was later reversed (2025), and FDA now treats NMN as a lawful dietary ingredient. The practical upshot: NMN’s availability has been unstable, and product quality across the category has been uneven. NR has had a smoother regulatory path. If you buy either, third-party testing matters more than usual.

The honest bottom line

• Safety looks reasonable short-term. The trials found good tolerability over weeks to a couple of months. Long-term safety in healthy people is simply not established.
• The benefit is unproven. You would be paying — with reasonable confidence — to raise a blood biomarker whose translation to health is unknown.
• This is not a foundation. Sleep, training, protein, and your cardiometabolic numbers all have vastly more evidence and belong first.

If the NAD+ story fascinates you and you can afford a well-tested product, NR or NMN is a low-to-moderate-risk experiment on yourself with an honest question mark over the payoff — not a mistake, but not a proven win either. The intellectually honest framing is: interesting biology, moving biomarker, missing outcome. Watch the trials; don’t mistake the biomarker for the benefit.